Sarcopenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Sarcopenia Market Outlook

Thelansis’s “Sarcopenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sarcopenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sarcopenia Overview

Sarcopenia is a musculoskeletal condition characterized by a progressive decrease in muscle mass and strength, especially in older people. Reduced levels of muscle strength, muscle quantity or quality, and physical performance are all included in the diagnosis of Sarcopenia. Such musculoskeletal deterioration has predictive value for adverse postoperative outcomes, higher rates of complications, death, and morbidity following major surgical procedures, and the inability to carry out daily tasks. Sarcopenia usually results from normal aging processes, which have many different and poorly understood causes. Reduced size and quantity of type II muscular fibers, inactivity, obesity, insulin resistance, lower serum concentrations of androgen and growth factors, insufficient protein consumption, and a blunted response of Muscle Protein Synthesis (MPS) to protein are some of the factors that lead to its development. Age-related decreases in serum concentrations of anabolic hormones: Anabolic hormones, including testosterone, human growth hormone (HGH), and Insulin-Like Growth Factor-1 (IGF-1), have a role in the formation, preservation, or regeneration of muscle tissue at normal physiological serum levels. Patients with Sarcopenia have age-related decreases in these hormones, which lends support to the underlying pathophysiology of the condition. Handgrip strength is one of the two techniques typically used to measure muscle strength in patients with suspected Sarcopenia. Consuming protein is a crucial component of nutritional therapy for Sarcopenia. According to the European Working Group on Sarcopenia in Older People (EWGSOP2), treatment plans should include healthy protein intake and exercise recommendations. Currently, there is no FDA-approved product for the treatment of sarcosis. For Sarcopenia, the combination of exercise therapy and nutrition may be more beneficial than either treatment alone.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: